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The problems of antimicrobial resist-ance are rapidly increasing, but there are large gaps in our knowledge and 
the research has been lacking.
The challenge of antimicrobial 
resistance
Antimicrobial resistance is a large and rap-
idly worsening public health burden, both 
in the UK and globally. In 2013, the UK 
Chief Medical Officer declared that anti-
microbial resistance ‘poses a catastrophic 
threat’, and the 2013 annual report 
includes a comprehensive overview of the 
threat of antimicrobial resistance 
(Department of Health, 2013). 
The Centers for Disease Prevention and 
Control (2013) have taken the unprec-
edented step of publishing a ‘threat report’ 
that gives a snapshot of the burden and 
threats posed by resistant bacteria and 
fungal pathogens (viral and parasitic dis-
eases are outside the remit of their report), 
describes the ‘potentially catastrophic con-
sequences of inaction’, and highlights the 
dwindling pipeline of new antibiotics. 
The US National Institutes of Health 
and European Commission have published 
action plans about how best to approach 
antimicrobial resistance. Groups such as 
Antibiotic Action and initiatives includ-
ing European Antibiotics Awareness Day 
(November 18 each year) have highlighted 
the threat to public health of antibiotic 
resistance. There are also concerns about 
the mass administration of antibiotics in 
animals (Centers for Disease Control and 
Prevention, 2013). These measures dem-
onstrate that major stakeholders are very 
concerned about what the future holds for 
the management of infectious diseases. 
Antimicrobial resistance 
research
Research into antimicrobial resistance is 
critical if the emerging challenges are to be 
addressed and risks mitigated. Pre-clinical 
research can investigate the discovery and 
development of new agents, clinical trials 
can help ascertain the efficacy of poten-
tially effective new chemical entities and 
test treatment regimens and combinations, 
and implementation research can ascertain 
the impact of antimicrobial resistance in 
populations. 
An earlier study on the funding awarded 
to UK institutions for antimicrobial resist-
ance research, published in 2013 (Head et 
al, 2013a), analysed comprehensively the 
awards made by public and philanthropic 
funders of research (there were very lim-
ited publicly available funding data from 
the private sector). The study estimated 
that there had been £2.6 billion of funding 
between 1997 and 2010 across all infec-
tious diseases (Head et al, 2013b); of this, 
just £102 million (3.9%) was allocated to 
antimicrobial resistance-related research. 
Given the potential adverse impact 
of antimicrobial resistance, the authors 
argue that there is inadequate funding 
allocated to antimicrobial resistance-relat-
ed research. Much of this research was 
focused on resistance in staphylococci 
(arguably a success story, given the time-
scales of the research and development 
investments under analysis here coincide 
with the peak and subsequent fall in 
rates of meticillin-resistant Staphylococcus 
aureus), with malaria and HIV the next 
most-studied diseases. There was virtually 
no investment specifically for resistance in 
gonorrhoea or Escherichia coli (or indeed 
Gram-negative bacteria generally), and 
few studies investigating drug-resistant 
tuberculosis. There was very little research 
into the adverse economic impact of anti-
microbial resistance in the UK. 
The lack of publicly available data on 
private sector investments for develop-
ment of new therapeutics and vaccines 
means there are data gaps in this analysis. 
To have a full picture of investments 
in antimicrobial resistance, private sector 
data should be made available without 
compromising commercial sensitivities. 
There is also an urgent need to pool 
research and development data from 
other research-intensive countries and the 
European Union to see if research gaps in 
the UK portfolio are being covered else-
where. Availability of global data will ena-
ble identification of global research gaps, 
and local and national areas of strength 
and expertise. Duplication of research can 
be reduced and multidisciplinary collabo-
rations enabled. 
Wisely investing in research 
and development 
Further to mapping the research land-
scape, there needs to be targeted invest-
ment in priority areas. Since 2010, there 
has been much progress in the UK in stra-
tegic investments in antimicrobial resist-
ance-related research via initiatives such as 
the UK Clinical Research Collaboration 
Translational Infections Research Initiative 
and the Health Innovation Challenge 
Fund. Following the UK Chief Medical 
Officer’s 2013 report, the National 
Institute for Health Research (2013), 
which mostly has a focus on translational 
research, issued a themed call for anti-
microbial resistance research across all of 
its research streams. There have also been 
reports by the Joint Working Group of 
Defra Antimicrobial Resistance 
Coordination and Advisory Committee 
on Antimicrobial Resistance and 
Healthcare Associated Infections entitled 
‘ESBLs: A Threat to Human and Animal 
Health?’ (Department of Health, 2012). 
The National Institutes of Health 
(2013) also announced the creation of a 
clinical research network, with specific 
focus on antibacterial resistance; funding 
for this project may eventually rise to 
$62 million, and the network will enable 
research into early-stage clinical evaluation 
of new antibacterial drugs, clinical trials to 
optimize currently licensed antibacterial 
drugs, testing diagnostics, and examin-
ing best practices in infection control 
programmes. Large-scale investments of 
this nature, which are concentrated into 
centres of excellence with outreach to 
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collaborating partners both locally and 
internationally, could be an effective model 
for public and philanthropic research and 
development policymakers to follow. 
The paucity of a pipeline of new anti-
biotics indicates, as in other priority areas 
of underinvestment where there could be 
substantial health gains, the need to create 
push and pull incentives to attract private 
sector investment or public–private part-
nerships (Fisk and Atun, 2008). Public–
private partnerships, such as the Innovative 
Medicines Initiative, supported jointly by 
the European Union and the European 
Federation of Pharmaceutical Industries 
and Associations, provide useful platforms 
for collaborative research. These novel col-
laborations involve both public funds and 
private investment, and can help to reduce 
the financial risk for pharmaceutical com-
panies (Goldman et al, 2013). 
Part of the Innovative Medicines Initiative 
is concentrated on identifying novel lead 
molecules for antibiotic development and 
this collaboration could be particularly 
important, in terms of highlighting the 
best direction for efficient antibiotic devel-
opment research and development pro-
grammes and appropriate models of how 
the private and public sectors can best 
work together (Head et al, 2013a). Other 
legislative issues surrounding the difficulties 
of carrying out trials, patents and licens-
ing could most likely be tailored towards 
encouraging pharmaceutical companies to 
invest, rather than acting as a barrier. 
Policy and politics
Antimicrobial resistance is a global problem 
and a threat to Europe, given the rising bur-
den and weak health systems in the coun-
tries with burden of drug-resistant infec-
tions that surround Europe, requiring con-
certed efforts in surveillance and action. 
However, global cooperation and leadership 
across nations with vastly different health-
care and surveillance systems (which may be 
woefully under-developed) is challenging, as 
is securing approval of a large number of 
politicians and health departments. 
In health policy terms, the powerful 
actors globally (including senior politi-
cians, senior scientists and influential indi-
viduals such as Bill Gates) can make a 
difference – there are success stories of 
worldwide collaboration involving coun-
tries and organizations such as the Global 
Fund, World Health Organization and 
Joint United Nations Programme on HIV/
AIDS in fighting HIV/AIDS or malaria, 
or for a number of neglected tropical dis-
eases but these successes are not universal. 
Philanthropic institutions such as the Bill 
and Melinda Gates Foundation have revi-
talized the fight against malaria and polio, 
and it is through similar partnership-based 
approaches that we should pursue greater 
investments in antimicrobial resistance 
research and development, as well as more 
immediately required attention in policy 
and health care (for example, in antibiotic 
prescribing and stewardship).
Priority areas for research 
investment
So many pathogens require urgent atten-
tion, including several Gram-negative bac-
teria (such as E. coli), Mycobacterium tuber-
culosis, Clostridium difficile and Neisseria 
gonorrhoeae. How can we develop new 
therapeutics, as well as management and 
best use of existing agents? 
Alongside this, disciplines such as epide-
miology, modelling, economics, policy and 
behavioural research, intervention studies 
aimed at reducing resistance and further 
pre-clinical research using new technolo-
gies (such as whole genome sequencing) 
and health systems research are areas to 
invest in (Head et al, 2013a). However, 
addressing a global problem will require 
concerted effort globally, and innovative 
models of investment and partnership 
with the private sector, with international 
political leadership, global recognition of 
the antimicrobial resistance problem and 
cooperation across nations. BJHM
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key points 
n	 Antimicrobial	resistance	is	now	widespread	and	very	much	a	global	problem.
n	 The	pipeline	of	new	antibiotics	is	dwindling.
n	 Historically,	there	has	been	a	lack	of	investment	in	research	into	antimicrobial	resistance.	In	2013,	
there	has	been	an	increased	focus	in	this	very	important	area	from	major	stakeholders	in	the	UK	
and	USA.	
n	 Is	this	focus	too	late?	Probably	not,	but	such	urgency	would	have	been	better	directed	15–20	years	ago.	
n	 Gram-negative	bacteria	(such	as	Escherichia coli,	Mycobacterium tuberculosis,	Clostridium difficile	and	
Neisseria gonorrhoeae	are	some	of	the	pathogens	with	the	greatest	resistance	to	existing	therapeutics.	
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